We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
As we proceed through the final quarter of the year, the time has come to evaluate what was hot and what not this year. After all, the year can be remembered for some negative events including a brutal sell-off in January thanks mainly to China-led woes and sharply falling oil prices, a Brexit-driven crash in June, persistent global growth worries and heightened volatility due to the presidential election in November.
Neither the S&P 500, nor the Dow Jones Industrial Average or the NASDAQ Composite has returned more than 5% so far (as of October 26, 2016), having gained 4.7%, 4.4% and 4.9%, respectively. The uptick reflects recent buoyancy in the tech space, better corporate earnings and a relief rally in the market at the start of Q3.
In such a situation, a look at the few worst-performing ETFs in the year-to-date frame makes more sense. Some of the ETFs have shed more than 50% so far this year and are creepy enough to spook investors prior to Halloween (read: 4 ETFs & Stocks to Treat You on Halloween and After).
Though the year has been pretty volatile, volatility related exchange-traded products ended up deep in the red. Other products like VelocityShares Daily Long VIX Short-Term ETN (VIIX) and ProShares VIX Short-Term Futures ETF (VIXY) have lost about 60.7% and 60.7%, respectively, this year (as of October 26, 2016).
Barclays Inverse U.S. Treasury Aggregate ETN – Down 39.5%
As the Fed has remained dovish in 2016 after enacting a liftoff in December 2015, bond yields have been extremely low for the most part of the year. Especially, the Brexit referendum dampened risk-on sentiments across the globe in mid-2016, inspired risk-off trade and dragged down U.S. Treasury bond yields. All these went against the product which is an inverse U.S. Treasury ETN (read: Top and Flop ETFs of 1H).
VanEck Vectors Solar Energy ETF (KWT - Free Report) – Down 35.1%
Solar stocks are victims of the general misconception that oil price and solar market fundamentals are directly related to each other. Further, weak earnings from a few industry bellwethers weighed on solar ETFs. Guggenheim Solar ETF (TAN) is down over 35% so far this year (as of October 26, 2016) (read: Solar ETFs Lose Their Shine on Weak Earnings).
BioShares Biotechnology Clinical Trials Fund (BBC - Free Report) – Down 33.3%
Biotech stocks and ETFs have been battered this year as investors lost appetite for risk that cursed this high-growth, high-beta segment. Also, increased regulatory scrutiny over high drug prices and political uncertainty surrounding healthcare reform in this election year have also acted as deterrents.
Image: Bigstock
4 Frightful ETFs of This Year
As we proceed through the final quarter of the year, the time has come to evaluate what was hot and what not this year. After all, the year can be remembered for some negative events including a brutal sell-off in January thanks mainly to China-led woes and sharply falling oil prices, a Brexit-driven crash in June, persistent global growth worries and heightened volatility due to the presidential election in November.
Neither the S&P 500, nor the Dow Jones Industrial Average or the NASDAQ Composite has returned more than 5% so far (as of October 26, 2016), having gained 4.7%, 4.4% and 4.9%, respectively. The uptick reflects recent buoyancy in the tech space, better corporate earnings and a relief rally in the market at the start of Q3.
In such a situation, a look at the few worst-performing ETFs in the year-to-date frame makes more sense. Some of the ETFs have shed more than 50% so far this year and are creepy enough to spook investors prior to Halloween (read: 4 ETFs & Stocks to Treat You on Halloween and After).
iPath S&P 500 VIX Short-Term Futures ETN (VXX - Free Report) – Down 60.9%
Though the year has been pretty volatile, volatility related exchange-traded products ended up deep in the red. Other products like VelocityShares Daily Long VIX Short-Term ETN (VIIX) and ProShares VIX Short-Term Futures ETF (VIXY) have lost about 60.7% and 60.7%, respectively, this year (as of October 26, 2016).
Barclays Inverse U.S. Treasury Aggregate ETN – Down 39.5%
As the Fed has remained dovish in 2016 after enacting a liftoff in December 2015, bond yields have been extremely low for the most part of the year. Especially, the Brexit referendum dampened risk-on sentiments across the globe in mid-2016, inspired risk-off trade and dragged down U.S. Treasury bond yields. All these went against the product which is an inverse U.S. Treasury ETN (read: Top and Flop ETFs of 1H).
VanEck Vectors Solar Energy ETF (KWT - Free Report) – Down 35.1%
Solar stocks are victims of the general misconception that oil price and solar market fundamentals are directly related to each other. Further, weak earnings from a few industry bellwethers weighed on solar ETFs. Guggenheim Solar ETF (TAN) is down over 35% so far this year (as of October 26, 2016) (read: Solar ETFs Lose Their Shine on Weak Earnings).
BioShares Biotechnology Clinical Trials Fund (BBC - Free Report) – Down 33.3%
Biotech stocks and ETFs have been battered this year as investors lost appetite for risk that cursed this high-growth, high-beta segment. Also, increased regulatory scrutiny over high drug prices and political uncertainty surrounding healthcare reform in this election year have also acted as deterrents.
Biotech ETFs like ALPS Medical Breakthroughs ETF (SBIO - Free Report) andPowerShares Dynamic Biotechnology and Genome (PBE - Free Report) have also shed 27.7% and 24.2%, respectively (as of October 26, 2016) (read: ETFs to Play as Biotech Juggles Election & Earnings).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>